LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 24 May 2017 Planned End Date changed from 1 Nov 2020 to 10 Aug 2021.
- 17 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Nov 2020.
- 13 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.